Pursuant to the three-year indefinite delivery/indefinite quantity contract, Cellectis will provide services such as generation of induced pluripotent stem (iPS) cell lines of research grade and differentiation of iPS cells for specific tissue cell type for research use.
Cellectis bioresearch CEO Marc Le Bozec said, "The second contract won through a NIH call for tenders dedicates our company as a leading competitor and an expert in the field in the United States."
Cellectis CEO Andre Choulika said, "This contract award granted by the most prestigious US research organization the NIH is a great recognition for Cellectis Group as the world’s largest biotech for the design, manufacture and engineer of human cells and cell lines for the drug discovery and development."